Home Blog of Signal Transduction Protein Tyrosine Kinase CSF-1R Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report

FGFR3-TACC3 fusions have been identified in patients with multiple cancer types, and tumors with these alterations are potentially sensitive to selective FGFR inhibitors. However, there are no FGFR inhibitors approved by the U.S. Food and Drug Administration for the treatment of patients with NSCLC with FGFR alterations. Here, we report a case of a patient with FGFR3-TACC3 fusion squamous NSCLC who achieved a radiographic response and disease control for 11 months on initial treatment with erdafitinib and subsequently obtained an additional 8 months of disease control after erdafitinib retreatment after 5 months of intervening chemotherapy. Further investigation into FGFR inhibitor treatment specifically and targeted therapy retreatment for patients with NSCLC may increase our therapeutic options for these patients.

 

Comments:

The case report you provided describes a patient with squamous non-small cell lung cancer (NSCLC) who had an FGFR3-TACC3 fusion. This fusion is found in various cancer types and is known to potentially respond to selective FGFR inhibitors. However, as of my knowledge cutoff in September 2021, there were no FGFR inhibitors approved by the U.S. Food and Drug Administration (FDA) specifically for treating NSCLC with FGFR alterations.

In the case you mentioned, the patient initially received treatment with erdafitinib, an FGFR inhibitor, and achieved a radiographic response with disease control for 11 months. After a 5-month period of chemotherapy, the patient received erdafitinib retreatment and achieved an additional 8 months of disease control. This suggests that retreatment with an FGFR inhibitor could be a viable option for patients who have previously responded to this type of therapy.

The case highlights the need for further investigation into FGFR inhibitor treatment and targeted therapy retreatment for patients with NSCLC. By conducting more research, we can potentially expand our therapeutic options for patients with NSCLC and FGFR alterations. It's worth noting that since my knowledge cutoff is in September 2021, there might have been advancements or new developments in FGFR inhibitor treatments for NSCLC beyond that date. It's always important to consult up-to-date medical literature and consult with healthcare professionals for the latest information and treatment options.

Related Products

Cat.No. Product Name Information
S8401 Erdafitinib Erdafitinib is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Erdafitinib also binds to RET (c-RET), CSF-1R, PDGFR-α/PDGFR-β, FLT4, Kit (c-Kit) and VEGFR-2 and induces cellular apoptosis.

Related Targets

VEGFR Apoptosis related c-RET PDGFR c-Kit CSF-1R FGFR